MORF(Delisted)
Morphic Holding·NASDAQ
--
--(--)
Signals Analysis
Bullish signal 0
Bearish signal 2
Significant Revenue Decline
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About MORF
Morphic Holding, Inc.
A biopharmaceutical company that develops a new generation of oral integrin therapies for the treatment of serious chronic diseases
35 Gatehouse Drive, A2, Waltham, Massachusetts 02451
--
Morphic Holding, Inc., was incorporated in August 2014 under the laws of the State of Delaware. They are a biopharmaceutical company applying their proprietary insights to integrins to discover and develop potentially first-in-class oral small molecule integrin therapies. Integrins are a target class of injectable blockbuster drugs with multiple approvals for the treatment of serious chronic diseases, including autoimmune, cardiovascular and metabolic diseases, fibrosis and cancer. Using their unique understanding of integrin structure and biology, they created the Morphic Integrin Technology Platform, or MInT Platform, to develop new product candidates designed to achieve the potency, high selectivity and drug properties required for oral administration.
Company Financials
EPS
MORF has released its 2024 Q1 earnings. EPS was reported at -0.91, versus the expected -0.93, beating expectations. The chart below visualizes how MORF has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
You can ask Aime
No Data
